RE:RE:RE:RE:AACR posters? Ooooh..bad target price $6.66. Let's round it to $6.70! There's zero downside for trying to pump up the sales, educate the HIV doctors and patients, and try everything you can to get sales growing at 15-20%. Especially for Trog where you get a customer for life. Levesque has always talked about any increase in sales funding the pipeline so he understands the importance. Any upside surprise there would be nice to see. It's not going to double the share, but it's a nice supporting factor if they can finally break the 500 patient level and move it to 6-700 Trog patients and add 100 to Egrifta for a year.
palinc2000 wrote: The current SP does not even fully value the 2 drugs presently being sold,,,,,Sales are finally gaining traction and pretty soon the market will have a reason to project higher sales which imo should be enough to propel the SP to 6.66$ US in the short term.....
.
Add to that some value to the pipeline which should increase with each bit of good news and or advancement